Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Evatanepag. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 known ✓ | P43116 | 12/20 | 0.98 |
| ▸ | CA12 | O43570 | 6/20 | 0.76 |
| ▸ | CA1 | P00915 | 6/20 | 0.76 |
| ▸ | CA2 | P00918 | 6/20 | 0.76 |
| ▸ | CA4 | P22748 | 6/20 | 0.76 |
| ▸ | CA9 | Q16790 | 6/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Evatanepag SCHEMBL29376960 | 0.99 | PTGER2 (1.00) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147493 | 0.99 | PTGER2 (1.00) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL533264 | 0.99 | PTGER2 (1.00) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147496 | 0.98 | PTGER2 (0.98) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147494 | 0.98 | PTGER2 (0.98) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6284518 | 0.93 | PTGER2 (0.88) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6278874 | 0.92 | PTGER2 (0.87) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL13407391 | 0.92 | PTGER2 (0.86) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6283458 | 0.91 | PTGER2 (0.85) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6276293 | 0.91 | PTGER2 (0.85) | PTGER2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046385-A1 | Polymorphs Of Prostaglandin Agonists And Methods For Making The Same | PFIZER PRODUCTS INC. (US) | 2011-02-24 | — | — | US | claimed |
| EP-2185516-A2 | POLYMORPHS OF 3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL)-PHENOXY)-ACETIC ACID SODIUM SALT OR A HYDRATE THEREOF AND METHODS FOR MAKING THE SAME | Pfizer Products Incorporated (US) | 2010-05-19 | — | — | EP | claimed |
| WO-2009027811-A2 | POLYMORPHS OF 3- ( ( (4-TERT-BUTYL-BENZYL) - (PYRIDINE-3-SULFONYL) -AMINO) -METHYL) -PHENOXY) -ACETIC ACID SODIUM SALT OR A HYDRATE THEREOF AND METHODS FOR MAKING THE SAME | PFIZER PRODUCTS INC. (US) | 2009-03-05 | — | — | WO | claimed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | claimed |
| US-20110046385-A1 | Polymorphs Of Prostaglandin Agonists And Methods For Making The Same | PFIZER PRODUCTS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046385-A1 | Polymorphs Of Prostaglandin Agonists And Methods For Making The Same | PFIZER PRODUCTS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| CN-101842356-A | Polymorphs of (3- (((4-tert-butylbenzyl) - (pyridine-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid sodium salt or hydrate thereof and process for producing the same | PFIZER PROD INC | 2010-09-22 | — | — | CN | disclosed |
| EP-2185516-A2 | POLYMORPHS OF 3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL)-PHENOXY)-ACETIC ACID SODIUM SALT OR A HYDRATE THEREOF AND METHODS FOR MAKING THE SAME | Pfizer Products Incorporated (US) | 2010-05-19 | — | — | EP | disclosed |
| EP-2185516-A2 | POLYMORPHS OF 3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL)-PHENOXY)-ACETIC ACID SODIUM SALT OR A HYDRATE THEREOF AND METHODS FOR MAKING THE SAME | Pfizer Products Incorporated (US) | 2010-05-19 | — | — | EP | disclosed |
| JP-2009137934-A | POLYMORPH OF PROSTAGLANDIN AGONIST AND METHOD FOR MAKING THE SAME | PFIZER PROD INC | 2009-06-25 | — | — | JP | disclosed |
| WO-2009027811-A3 | POLYMORPHS OF 3- ( ( (4-TERT-BUTYL-BENZYL) - (PYRIDINE-3-SULFONYL) -AMINO) -METHYL) -PHENOXY) -ACETIC ACID SODIUM SALT OR A HYDRATE THEREOF AND METHODS FOR MAKING THE SAME | PFIZER PROD INC (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009027803-A2 | POLYMORPHS OF (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL)- PHENOXY)-ACETIC ACID, FREE ACID | PFIZER PRODUCTS INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027811-A2 | POLYMORPHS OF 3- ( ( (4-TERT-BUTYL-BENZYL) - (PYRIDINE-3-SULFONYL) -AMINO) -METHYL) -PHENOXY) -ACETIC ACID SODIUM SALT OR A HYDRATE THEREOF AND METHODS FOR MAKING THE SAME | PFIZER PRODUCTS INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027811-A2 | POLYMORPHS OF 3- ( ( (4-TERT-BUTYL-BENZYL) - (PYRIDINE-3-SULFONYL) -AMINO) -METHYL) -PHENOXY) -ACETIC ACID SODIUM SALT OR A HYDRATE THEREOF AND METHODS FOR MAKING THE SAME | PFIZER PRODUCTS INC. (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046385-A1 | Polymorphs Of Prostaglandin Agonists And Methods For Making The Same | PTGER1, PTGER3, PTGER4 | PTGER2 4/4885CA12 3977/4885CA1 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.